From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
Synonyms RU-2010
ATC code
CAS Number
PubChem CID
ECHA InfoCard 100.011.544
Chemical and physical data
Formula C20H22O2
Molar mass 294.387 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Norgestrienone (INN) (brand name Ogyline, Planor, Miniplanor; former developmental code name RU-2010), also known as Δ9,11-norethisterone[1] or 17α-ethynyltrienolone (17α-ethynyltrenbolone), as well as 17α-ethynylestra-4,9,11-trien-17β-ol-3-one, is a steroidal progestin related to norethisterone that is used as a hormonal contraceptive, sometimes in combination with ethinylestradiol.[2][3][4][5] It was developed by Roussel Uclaf and is registered for use only in France.[5][6] Under the brand name Planor, it is or was marketed in France as 2 mg norgestrienone and 50 μg ethinylestradiol tablets.[7] Norgestrienone has been found to possess similar affinity for the progesterone receptor and androgen receptor,[8] and in accordance, has some androgenic activity.[9][10][11] The drug was first described in the literature in 1965.[10] Gestrinone is the 13β-ethyl variant or 18-methyl derivative of norgestrienone.[12]

See also[edit]


  1. ^ J.P. Lavery; J.S. Sanfilippo (6 December 2012). Pediatric and Adolescent Obstetrics and Gynecology. Springer Science & Business Media. pp. 236–. ISBN 978-1-4612-5064-7. 
  2. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 887–. ISBN 978-1-4757-2085-3. 
  3. ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 202–. ISBN 978-94-011-4439-1. 
  4. ^ Diaz, S.; Pavez, M.; Quinteros, E.; Diaz, J.; Robertson, D. N.; Croxatto, H. B. (1978). "Clinical trial with subdermal implants containing norgestrienone". Contraception. 18 (4): 429–440. PMID 720075. doi:10.1016/0010-7824(78)90027-6. 
  5. ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 751–. ISBN 978-3-88763-075-1. 
  6. ^ John L. McGuire (2000). Pharmaceuticals, 4 Volume Set. Wiley. p. 1580,1599. ISBN 978-3-527-29874-7. 
  7. ^ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 455–. ISBN 978-92-832-1291-1. 
  8. ^ Loughney DA, Schwender CF (1992). "A comparison of progestin and androgen receptor binding using the CoMFA technique". J. Comput. Aided Mol. Des. 6 (6): 569–81. PMID 1291626. doi:10.1007/bf00126215. 
  9. ^ Julius Axelrod (1 January 1982). Biochemical Actions of Hormones. Academic Press. ISBN 978-0-12-452809-3. 
  10. ^ a b Christian Lauritzen; John W. W. Studd (22 June 2005). Current Management of the Menopause. CRC Press. pp. 45–. ISBN 978-0-203-48612-2. 
  11. ^ R.T. Di Giulio; E. Monosson (6 December 2012). Interconnections Between Human and Ecosystem Health. Springer Science & Business Media. pp. 60–. ISBN 978-94-009-1523-7. 
  12. ^ Victor Gomel; Andrew Brill (27 September 2010). Reconstructive and Reproductive Surgery in Gynecology. CRC Press. pp. 90–. ISBN 978-1-84184-757-3.